Health officials are sending a warning to residents in Gulf Coast states after eight people are dead from the flesh-eating bacteria called Vibrio vulnificus.
On Thursday, July 31, the Louisiana Department of Heath confirmed 17 cases of the flesh-eating bacteria this year, all of which resulted in hospitalizations. Additionally four cases resulted in death. About 75% of those cases were due to wound infection via seawater.
Additionally, the Florida Department of Health confirmed 13 cases and four deaths from Vibrio this year. Both Mississippi and Alabama have also reported single cases, neither fatal.
Biotech companies large and small are using AI to make drugs cheaper, faster and with a higher probability of success. Here’s how Boston-area ones are harnessing the technology.
Surgeons at The Johns Hopkins Hospital have performed the world’s first total penis and scrotum transplant.
The patient suffered a devastating injury several years ago from an improvised explosive device while serving in Afghanistan. He is now recovering at the hospital after the 14-hour procedure in late March, which repaired his abdominal wall, gave him a new scrotum and attached a donor penis.
“We are optimistic he will regain near-normal urinary and sexual functions,” said W. P. Andrew Lee, director of plastic and reconstructive surgery at the Johns Hopkins University School of Medicine.
Background False cardiac troponin (cTn) elevations from non-cardiac causes are a major concern. We aimed to assess terminal renal failure as a possible non-cardiac cause of elevated high-sensitivity cTnT (hs-cTnT) concentrations using renal transplantation as an in vivo model of rapid restoration of renal function.
Methods We analysed consecutive patients with end-stage renal disease (ESRD) undergoing renal transplantation at a single centre. Patients with perioperative myocardial infarction or injury were excluded. Changes in hs-cTnT and creatinine were measured pretransplant and at four post-transplant intervals (day 1, days 2–5 and days 14–180). A decrease of ≥25% in hs-cTnT within 24 hours post-transplant was deemed evidence of renal clearance recovery.
Results Among 45 patients (median age 67 years, 31% women), the median pretransplant plasma creatinine concentration was 608 μmol/L (IQR 482–830), and fell to 425 μmol/L (IQR 337–619) on day 1289 μmol/L (IQR 201–492) on days 2–5 and 126 μmol/L (IQR 103–191) on days 14–180 (p0.001, p0.001 and p=0.003, respectively). The median pretransplant hs-cTnT concentration was 48 ng/L (IQR 34–70). It fell to 26 ng/L (IQR 15–38; geometric mean of relative change 36%) on day 1 (p0.001) and then remained constant on days 2–5 (26 ng/L (IQR 18–35)) and days 14–180 (25 ng/L (IQR 20–30), p=ns).
The ER-100 drug candidate reverses aging in mice, and David Sinclair says human trials start soon. Is this a magic pill for aging? Dr. Aubrey de Grey discusses the latest advances in life-extension research.
Our story begins on X, where user “rand_longevity” wrote, “Aging will be reversible in humans within 8 years”, to which Dr. David Sinclair replied, “8 years? After successful non-human primate trials, human age reversal trials are set to begin in 6 months”, later naming the ER-100 drug candidate.
Life Biosciences ER-100 drug candidate leverages partial epigenetic programming using 3 of the 4 Yamanaka factors to promote cellular rejuvenation to a younger state without the loss of cell identity. They believe this will help prevent or reverse age-related diseases at a root level — but they’re not the only organization pursuing life-extension research.
Dr. de Grey’s own research has focused primarily on accumulated side effects from metabolism, embodied in the title of his 1999 book, “The Mitochondrial Free Radical Theory of Aging”.
Dr. de Grey is well-known as one of the top gerontology and life-extension scientists in the world, and his own work has also been successful in extending the lifespan of lab animals. In this program, he discusses his work and some of the key elements of living a longer, healthier life.
DISCLAIMER: This program is a discussion is about ongoing scientific research, and is NOT providing medical advice. Please consult your doctor before starting any supplements, beginning an exercise routine, or undertaking lifestyle changes.
A new artificial intelligence (AI) tool could make it much easier—and cheaper—for doctors and researchers to train medical imaging software, even when only a small number of patient scans are available.
The AI tool improves upon a process called medical image segmentation, where every pixel in an image is labeled based on what it represents—cancerous or normal tissue, for example. This process is often performed by a highly trained expert, and deep learning has shown promise in automating this labor-intensive task.
The big challenge is that deep learning-based methods are data hungry—they require a large amount of pixel-by-pixel annotated images to learn, explained Li Zhang, a Ph.D. student in the Department of Electrical and Computer Engineering at the University of California San Diego. Creating such datasets demands expert labor, time and cost. And for many medical conditions and clinical settings, that level of data simply doesn’t exist.
A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ovarian cancer, outperforming the current gold standard. This research, published in the July issue of The Journal of Nuclear Medicine, lays the foundation for further development of radionuclide therapies targeting CSCs, offering renewed hope for more effective treatment options and improved outcomes for patients.
CSCs are highly tumorigenic, self-renewable cells that play a key role in tumor relapse, metastasis, and therapy resistance. Although the clinical significance of eliminating CSCs is clearly recognized and CSC immunotherapies have been examined in preclinical and clinical evaluations, the development of such therapies remains a challenge.
“Radioimmunotherapy enables precise, target-specific delivery of particulate radiation to cancer-associated antigens, while minimizing off-target accumulation and increasing tumor retention and irradiation, which makes it a promising choice for targeting CSCs,” stated Jürgen Grünberg, Ph.D., senior scientist at the Center for Radiopharmaceutical Sciences, Center for Life Sciences at the Paul Scherrer Institute in Villigen, Switzerland.
A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key driver in T-cell development and function.
These so-called soluble Notch agonists can be broadly applied to optimize clinical T-cell production and advance immunotherapy development.
Notch signaling is central to many cellular differentiation processes and is essential in transforming human immune cells into T-cells that target viruses and tumors. But activating Notch signaling in the laboratory has posed a challenge.
Researchers have discovered a protein which is critical for steering melanoma cancer cells as they spread throughout the body. The malignant cells become dependent on this protein to migrate, pointing to new strategies for impeding metastasis.
The protein eIF2A is generally thought to spring into action when a cell is under stress, helping ribosomes launch protein synthesis. But according to a study published in the journal Science Advances, eIF2A has a completely different role in melanoma, helping cancerous cells control movement.
“Malignant cells that metastasize need to make their way through tissues in order to invade proximal or distant organs. Targeting eIF2A could be a new strategy to impede melanoma breaking free and seeding tumors elsewhere,” says Dr. Fátima Gebauer, corresponding author of the study and researcher at the Center for Genomic Regulation (CRG) in Barcelona.
